Oriental Aromatics Ltd

- No explicit mention of any new fundraising through debt or equity in the provided transcript. - Current finance costs have increased due to higher working capital borrowings and GST interest charges. - Net debt-to-equity ratio improved to 0.30x as of March 31, 2024, from 0.34x in the previous year, despite investments in CAPEX. - Management discussed ongoing investments in Mahad and Baroda plants but did not indicate raising new debt or equity for these. - Interest cost guidance for the next financial year is INR 17-18 crore, indicating existing debt servicing but no new major debt raising. - Overall, no clear plans shared regarding fresh debt or equity fundraising in near term.

- Oriental Aromatics has ongoing investments in two major CAPEX projects at Mahad and Baroda, which are at advanced stages of commercial production with trial runs currently underway. - The new capacities are expected to contribute to revenue growth starting effectively from Q3 FY '24-'25 or Q1 FY '25-'26. - No alarming new CAPEX is expected in the camphor business side, though existing supply-demand gaps persist. - The asset turnover ratios for the new CAPEX are approximately 1.2 for Mahad (Greenfield) and around 1.5 for Brownfield expansions. - The company is cautiously optimistic about utilization and breakeven timelines, aiming for 60%-80% utilization in the first year of operations. - Focus remains on profitable growth with strategic capacity utilization without immediate plans for large-scale new investments beyond current projects.

- The company is cautiously optimistic about growth in the Aroma Chemicals and Fragrance & Flavor divisions driven by steady demand revival and reduced raw material prices. - New capacities in Mahad and Baroda are at advanced trial stages; commercial contributions expected from Q3 FY '24-'25 and fully from Q1 FY '25-'26. - Expected revenue from new capacities: asset turnover around 1.2 to 1.5 times CAPEX; projections suggest ~Rs. 100-120 crores top line from new units in FY '25. - Capacity utilization for new plants targeted at 60-80% in the first year. - Export contribution increased from 30% to 44%, led by Specialty Ingredients and Fragrance & Flavor divisions. - Continued focus on profitable growth, with a balanced product mix across three verticals (~33% each). - Targeting EBITDA margins of 10-12% in FY '25 or FY '26 as business stabilizes and demand improves.

- The management is cautiously optimistic about demand revival and expects steady growth in the Aroma Chemicals and Fragrance & Flavor divisions in FY '25. - They project EBITDA margins improvement, targeting between 10% to 12% in the near future, likely by FY '26. - New capacities (e.g., Mahad and Baroda plants) are expected to contribute meaningfully to revenues from FY '25, with anticipated utilization between 60% to 80%. - The company aims for profitable growth across all segments despite challenges like camphor powder and terpene chemicals overcapacity. - Interest costs are expected around INR 17-18 crore, with depreciation increasing due to new CAPEX, reflecting planned capacity expansions. - Cash flow improvements are noted with operating cash flow at INR 142 crore in FY '24, aiding financial stability for growth. - Overall, management anticipates volume growth, improved profitability, and EPS recovery aligned with business stability and expansion efforts.

- The transcript does not explicitly mention the current or expected order book or pending orders in quantified terms. - However, management expressed cautious optimism about increasing demand and growth in their Specialty Ingredients and Fragrance and Flavor divisions. - Trial production is ongoing in new capacities at Mahad and Baroda, with commercial contributions expected within 6 to 9 months, implying an expanding order inflow for these new plants. - Customer feedback indicates healthy demand with expected first-year utilization of 60% to 80% for the newly commissioned plants. - The company is focused on profitable growth and expects steady demand recovery across divisions despite challenges in the camphor and terpene chemical segments. - No exact figures or timelines on the complete order book or pending orders were disclosed during the call.